Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Monopar Therapeutics Inc. - Common Stock
(NQ:
MNPR
)
59.99
+4.79 (+8.69%)
Streaming Delayed Price
Updated: 11:51 AM EDT, May 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Monopar Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
November 14, 2025
Via
Benzinga
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
October 13, 2025
Via
Benzinga
Recap: Monopar Therapeutics Q4 Earnings
↗
March 28, 2024
Via
Benzinga
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
↗
September 25, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout
↗
September 15, 2025
The company is working on a treatment for a rare, inherited disease that causes copper to build up in the body.
Via
Investor's Business Daily
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
June 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
March 21, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 20, 2024
Via
Benzinga
3 Momentum Stocks Soaring Into 2025 and Beyond
December 03, 2024
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.
Via
MarketBeat
Topics
Stocks
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 28, 2024
Via
Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
October 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 25, 2024
Via
Benzinga
What's Going On With Monopar Therapeutics Shares Friday?
↗
October 25, 2024
Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 25, 2024
Via
Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
↗
October 25, 2024
Via
Benzinga
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
↗
October 24, 2024
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.
Via
Benzinga
Topics
Stocks
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
↗
October 24, 2024
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 01, 2024
Via
Benzinga
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
↗
September 12, 2024
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.
Via
Benzinga
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
↗
August 09, 2024
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
↗
June 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 07, 2024
Via
Benzinga
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
↗
June 05, 2024
Penny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why the SEC has a warning about them too.
Via
InvestorPlace
Topics
Regulatory Compliance
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
↗
June 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 09, 2024
Via
Benzinga
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
↗
May 03, 2024
Via
Benzinga
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023
↗
March 28, 2024
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
